The assay revealed novel insights and data at a single-cell resolution on the impact of PD1 and LAG3 inhibition (both separately and in combination) on CD8+ T cells activation by exposure to antigen-presenting cells such as dendritic cells and on CD8+ T cells tumor-killing function. The gene discussed is LAG3; the disease is neoplasm.